CN1120722C - A topical medicine for treating vitiligo, leukoplakia vulvae and other leukoplakia, and its preparation method - Google Patents
A topical medicine for treating vitiligo, leukoplakia vulvae and other leukoplakia, and its preparation method Download PDFInfo
- Publication number
- CN1120722C CN1120722C CN99114078A CN99114078A CN1120722C CN 1120722 C CN1120722 C CN 1120722C CN 99114078 A CN99114078 A CN 99114078A CN 99114078 A CN99114078 A CN 99114078A CN 1120722 C CN1120722 C CN 1120722C
- Authority
- CN
- China
- Prior art keywords
- leukoplakia
- fructus psoraleae
- stigma croci
- vitiligo
- dihydroxyacetone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 206010047642 Vitiligo Diseases 0.000 title claims abstract description 13
- 208000002741 leukoplakia Diseases 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 230000000699 topical effect Effects 0.000 title 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims abstract description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000003756 stirring Methods 0.000 claims abstract description 15
- 238000002156 mixing Methods 0.000 claims abstract description 14
- 229940120503 dihydroxyacetone Drugs 0.000 claims abstract description 13
- 150000002576 ketones Chemical class 0.000 claims abstract description 10
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims abstract description 9
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims abstract description 9
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims abstract description 9
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960004544 cortisone Drugs 0.000 claims abstract description 9
- 229960003632 minoxidil Drugs 0.000 claims abstract description 9
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 7
- 230000001954 sterilising effect Effects 0.000 claims abstract description 6
- 238000001914 filtration Methods 0.000 claims abstract description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 12
- 229960004961 mechlorethamine Drugs 0.000 claims description 12
- 206010025421 Macule Diseases 0.000 claims description 10
- 244000147568 Laurus nobilis Species 0.000 claims description 9
- 235000017858 Laurus nobilis Nutrition 0.000 claims description 9
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 239000012675 alcoholic extract Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 abstract description 4
- 229960003639 laurocapram Drugs 0.000 abstract description 4
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 239000005974 Chlormequat Substances 0.000 abstract 1
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- JUZXDNPBRPUIOR-UHFFFAOYSA-N chlormequat Chemical compound C[N+](C)(C)CCCl JUZXDNPBRPUIOR-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 229960002868 mechlorethamine hydrochloride Drugs 0.000 abstract 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- 238000002791 soaking Methods 0.000 abstract 1
- 241001446509 Psoralea Species 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000000774 hypoallergenic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- UOQFZGVGGMHGEE-UHFFFAOYSA-N 1,1-dihydroxypropan-2-one Chemical class CC(=O)C(O)O UOQFZGVGGMHGEE-UHFFFAOYSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to an externally applied medicine for treating vitiligo, leukoplakia vulvae and other leukoplakia and a preparation process thereof. The components and the total weight ratio of the components are as follows: 0.005-0.1% of mechlorethamine hydrochloride, 0.5-2% of dihydroxyacetone, 88-93.4% of fructus psoraleae, 5-10% of 95% of alcohol extract of Tibetan safflower and 1-5% of laurocapram * ketone. In addition to the above components, the components can be added, and the ratio of the added components in the total weight is as follows: 0.5 to 3 percent of cortisone, 1 to 3 percent of minoxidil, 0.1 to 1 percent of borneol and 0.1 to 1 percent of musk. The preparation method comprises collecting stigma croci Sativi and fructus Psoraleae; pulverizing, sieving, mixing, and stirring; soaking in 95% ethanol of stigma croci Sativi and fructus Psoraleae; filtering, adding chlormequat hydrochloride, dihydroxyacetone and laurocapram, mixing and stirring uniformly; and (6) sterilizing and packaging. The advantages are that: the clinical 100 cases prove that the medicine is applied to patients once a day, the effect is taken in 5 days quickly and 20 days slowly, the side effect is small, the effective rate is 100%, and the cure rate is over 60%.
Description
Technical field
That the present invention relates to is a kind of external used medicine and preparation technology thereof who treats vitiligo, leukoplakia vulvae and other white macula.Belong to technical field of pharmaceuticals.
Background technology
Prior art such as white insane spirit, with its treatment vitiligo take effect slowly, cure rate is low, though medicines such as also useful Fructus Psoraleae, mustine hydrochlcride are treated vitiligo, lacks the cooperation that can quicken dye and have the medicine of blood circulation-promoting functions, causes therapeutic effect not good enough.
Summary of the invention
The objective of the invention is to external used medicine and preparation technology thereof that defective at above-mentioned existence proposes a kind of instant effect, treatment vitiligo, leukoplakia vulvae and other white macula that cure rate is high.Technical solution of the present invention: each composition and shared its gross weight ratio: mustine hydrochlcride 0.005%～0.1%, dihydroxyacetone 0.5%～2%, 95% alcoholic extract of the Fructus Psoraleae of 88%-93.4% and 5%～10% Stigma Croci sativi, Laurel nitrogen ketone 1%～5%.
Except that mentioned component, can increase composition, increase the ratio of the shared gross weight of composition: cortisone 0.5%～3%, loniten 1%～3%, Borneolum Syntheticum 0.1%～1%, Moschus 0.1%～1%.
Step of preparation process branch (1) is got Stigma Croci sativi 5%～10%, Fructus Psoraleae 88%～93.4% earlier; (2) pulverize, with mixing and stirring behind 40 mesh sieves; (3) putting into is that the alcohol content of 2～3 times of Stigma Croci sativi, Fructus Psoraleae material is 95% ethanol, soaks at normal temperatures 15～20 days; (4) filter 2～3 times with centrifuge, filtering solution should be clear thoroughly; (5) add mustine hydrochlcride 0.005%～0.1%, dihydroxyacetone 0.5%～2%, Laurel nitrogen ketone 1%～5% mixing and stirring; (6) sterilization, packing.
In processing step (5), add cortisone 0.5%～3%, loniten 1%～3%, Borneolum Syntheticum 0.1%～1%, Moschus 0.1%～1% again.
Advantage of the present invention: the patient applies ointment once every day, then takes effect in 5 days soon, then takes effect in 20 days slowly, and side effect is little, and as if adding Moschus and loniten energy blood vessel dilating again, promoting infiltration to strengthen the absorption of skin to medicine, the adding cortisone can be hypo-allergenic, heightens the effect of a treatment.
The specific embodiment
Embodiment 1
(1) gets 0.005 kilogram of mustine hydrochlcride, 0.5 kilogram of dihydroxyacetone, 93.4 kilograms of Fructus Psoraleaes, 5 kilograms of Stigma Croci sativi, 1 kilogram of Laurel nitrogen ketone; (2) Stigma Croci sativi, Fructus Psoraleae are pulverized, used 40 mesh sieves, mixing and stirring; (3) get 196.8 kilograms 95% ethanol, the back Stigma Croci sativi that will stir, Fructus Psoraleae are put into ethanol, soak at normal temperatures 18 days; (4) filter 2 times with centrifuge, it is clear that solution is; (5) with mustine hydrochlcride, dihydroxyacetone, Laurel nitrogen ketone and above-mentioned clear solution mixing and stirring; (6) sterilization, packing.
Embodiment 2
(1) gets 0.1 kilogram of mustine hydrochlcride, 2 kilograms of dihydroxyacetones, 88 kilograms of Fructus Psoraleaes, 7 kilograms of Stigma Croci sativi, 2.5 kilograms of Laurel nitrogen ketone; (2) Stigma Croci sativi, Fructus Psoraleae are pulverized with pulverizer after, use 40 mesh sieves, mixing and stirring; (3) get 285 kilograms of Stigma Croci sativi, the triple ethanol of Fructus Psoraleae (containing 95%), the Stigma Croci sativi and the Fructus Psoraleae of mixing and stirring are put into ethanol immersion 15 days; (4) with centrifuge filter 23 time, it is clear that solution is; (5) with mustine hydrochlcride, dihydroxyacetone, laurocapram and above-mentioned clear solution mixing and stirring; (6) sterilization, packing.
Embodiment 3
(1) gets 0.005 kilogram of mustine hydrochlcride, 0.5 kilogram of dihydroxyacetone, 91.5 kilograms of Fructus Psoraleaes, 5 kilograms of Stigma Croci sativi, 1 kilogram of Laurel nitrogen ketone, 0.5 kilogram of cortisone, 1 kilogram of loniten, 0.1 kilogram of Borneolum Syntheticum, 0.1 kilogram in Moschus; (2) Stigma Croci sativi, Fructus Psoraleae are pulverized with pulverizer after, use 40 mesh sieves, and mixing and stirring; (3) get 193 kilograms of 95% ethanol, Stigma Croci sativi, the Fructus Psoraleae of mixing and stirring are put into ethanol, soaked at normal temperatures 20 days; (4) filter 2 times with centrifuge, it is clear that solution is; (5) with mustine hydrochlcride, dihydroxyacetone, Laurel nitrogen single ketones, cortisone, loniten, Borneolum Syntheticum, Moschus and above-mentioned clear solution mixing and stirring; (6) sterilization, packing.
Because vitiligo, the cause of disease of leukoplakia vulvae and other white macula is not clear and definite as yet so far, prior art all still can not have curative effect preferably to its disease, adopt the present invention to produce ideal effect from clinical 100 example checkings, be that the patient applies ointment once every day, just take effect in 5-20 days and obviously maybe can recover the color of this skin.This mainly is that formula combination of the present invention is more reasonable, select medicine proper, the mustine hydrochlcride in the prescription is to be commonly used for antitumor drug, and it to the treatment of precancerosis degeneration white macula effectively, dihydroxyacetone has pigmentation, adding rare Chinese medicine Stigma Croci sativi, Moschus then have the stronger effect of invigorating blood circulation, and laurocapram, loniten have expansible blood vessel, promote infiltration, strengthen the absorption of skin to medicine, dihydroxyacetone can quicken dye, make skin recover normal color, cortisone is hypo-allergenic, strengthens curative effect.The present invention integrates that medicine is invigorated blood circulation, dye, promotion infiltration, Polyglucan, takes effect so have rapidly, improves cure rate, reduces the characteristics of side effect, and it is the good recipe for the treatment of vitiligo, leukoplakia vulvae and other white macula disease at present.
Claims (4)
1, a kind of external used medicine for the treatment of vitiligo, leukoplakia vulvae and other white macula is characterized in that shared its gross weight ratio of each composition:
Mustine hydrochlcride 0.005%～0.1%,
Dihydroxyacetone 0.5%～2%,
The Fructus Psoraleae of 88%-93.4% and
95% alcoholic extract of 5%～10% Stigma Croci sativi,
Laurel nitrogen ketone 1%～5%.
2, according to the described a kind of external used medicine for the treatment of vitiligo, leukoplakia vulvae and other white macula of claim 1, it is characterized in that composition can increase, reach the weight ratio that they respectively account for: cortisone 0.5～3%, loniten 1%～3%, Borneolum Syntheticum 0.1%～1%, Moschus 0.1%～1%.
3, a kind of preparation technology who treats the external used medicine of vitiligo, leukoplakia vulvae and other white macula is characterized in that processing step branch (1) gets Stigma Croci sativi 5%～10%, Fructus Psoraleae 88%～93.4% earlier; (2) pulverize, with mixing and stirring behind 40 mesh sieves; (3) putting into is that the alcohol content of 2～3 times of Stigma Croci sativi, Fructus Psoraleae material is 95% ethanol, soaks at normal temperatures 15～20 days; (4) filter 2～3 times with centrifuge, filtering solution should be clear thoroughly; (5) add mustine hydrochlcride 0.005%～0.1%, dihydroxyacetone 0.5%～2%, Laurel nitrogen ketone 1%～5% mixing and stirring; (6) sterilization, packing.
4, a kind of preparation technology who treats the external used medicine of vitiligo, leukoplakia vulvae and other white macula according to claim 3 is characterized in that also can adding in the processing step (5) cortisone 0.5%～3%, loniten 1%～3%, Borneolum Syntheticum 0.1～1%, Moschus 0.1%～1%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99114078A CN1120722C (en) | 1999-02-25 | 1999-02-25 | A topical medicine for treating vitiligo, leukoplakia vulvae and other leukoplakia, and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99114078A CN1120722C (en) | 1999-02-25 | 1999-02-25 | A topical medicine for treating vitiligo, leukoplakia vulvae and other leukoplakia, and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1238210A CN1238210A (en) | 1999-12-15 |
| CN1120722C true CN1120722C (en) | 2003-09-10 |
Family
ID=5277201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99114078A Expired - Fee Related CN1120722C (en) | 1999-02-25 | 1999-02-25 | A topical medicine for treating vitiligo, leukoplakia vulvae and other leukoplakia, and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1120722C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327836C (en) * | 2000-11-01 | 2007-07-25 | 张若飞 | Composition for treating leukoderma |
| CN1302770C (en) * | 2004-12-17 | 2007-03-07 | 辽宁正鑫药物研究有限公司 | Gel of chlormethine hydrochloride and preparing method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1085097A (en) * | 1993-08-05 | 1994-04-13 | 周树臻 | Treat leukodermic external-use tincture and compound method thereof |
| CN1098919A (en) * | 1993-08-17 | 1995-02-22 | 邓锦煌 | Vitiligo tincture |
| CN1185970A (en) * | 1998-01-06 | 1998-07-01 | 宋守金 | External use medicine for vitiligo |
| CN1192368A (en) * | 1998-04-17 | 1998-09-09 | 成中田 | External use pharmaceutical compositions for treating vitiligo and its prepn. method |
-
1999
- 1999-02-25 CN CN99114078A patent/CN1120722C/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1085097A (en) * | 1993-08-05 | 1994-04-13 | 周树臻 | Treat leukodermic external-use tincture and compound method thereof |
| CN1098919A (en) * | 1993-08-17 | 1995-02-22 | 邓锦煌 | Vitiligo tincture |
| CN1185970A (en) * | 1998-01-06 | 1998-07-01 | 宋守金 | External use medicine for vitiligo |
| CN1192368A (en) * | 1998-04-17 | 1998-09-09 | 成中田 | External use pharmaceutical compositions for treating vitiligo and its prepn. method |
Non-Patent Citations (3)
| Title |
|---|
| 解放军医学杂志 1991.03.01 薛长连，"中医药综台疗白癜风800例临床报告";铁道医学 1995-05-01 罗少华等白II涂剂的制备及应用 * |
| 解放军医学杂志 1991.03.01 薛长连，"中医药综台疗白癜风800例临床报告" * |
| 铁道医学 1995-05-01 罗少华等白II涂剂的制备及应用 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1238210A (en) | 1999-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU596701B2 (en) | Antioxidant composition and production method thereof | |
| CN108888676A (en) | A kind of Chinese medicine composition and preparation method thereof for treating eczema | |
| CN107411987A (en) | A kind of clear acne compound essential oil of face and preparation method thereof | |
| KR101752232B1 (en) | Manufacturing Method of Composition for Hair growth promotion and Hair loss prevention | |
| CN1120722C (en) | A topical medicine for treating vitiligo, leukoplakia vulvae and other leukoplakia, and its preparation method | |
| CN1055013C (en) | Method for prepn. of Chinese medicinal external application ointment for diminishing inflammation, stopping pain and setting fracture | |
| CN107375064A (en) | A kind of spot-dispelling liquid and preparation method thereof | |
| CN103816086A (en) | Whitening traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN101278892B (en) | Functional cosmetics additive agent and method of producing the same | |
| KR101082820B1 (en) | Preparation method for functional composition derived from natural material for alleviating atopic dermatitis | |
| CN113388460A (en) | Faint scent type perfumed soap containing peony flowers and preparation method thereof | |
| CN1221786A (en) | Medicinal soap containing propolis | |
| CN101564426B (en) | Medicament for external use for treating onychomycosis | |
| CN1169465A (en) | Multifunction synthetic detergent | |
| CN109170467A (en) | A kind of preparation method of the solid beverage with effect of weight reducing | |
| CN109260083A (en) | A kind of antiallergic reparation water and preparation method thereof containing various plants extracting solution | |
| CN1113782A (en) | Preparing method for lucid ganoderma beautifying and life-prolonging wine | |
| CN1176134A (en) | Active aloe glue | |
| CN1059798C (en) | Infusion for burn and scald | |
| CN1098093C (en) | Kouchuangjin (wiping out aphtha) and its preparation technology | |
| CN1101697C (en) | Exterior-applied Chinese medicine for treating bone fracture and its preparing process | |
| CN1371982A (en) | Method for preparing saffron chrysanthemum health care wine | |
| CN1235030A (en) | Composite oral liquid of Gaolining and preparing method thereof | |
| CN116536124A (en) | Wild glossy ganoderma and chrysanthemum wine with bear gall gold powder | |
| RU2155055C1 (en) | Agent for vitiligo treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20030910 Termination date: 20160225 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |